PPC4 Antibody

Platelet Factor 4 (PF4) Antibodies

PF4 antibodies are associated with heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT). Key features include:

Programmed Cell Death Protein 4 (PDCD4) Antibodies

PDCD4 antibodies, such as ab80590, are critical in cancer research:

Anti-PDCD4 Antibody (ab80590)

• Mechanism: Inhibits EIF4A helicase activity, modulating JUN kinase and MAP4K1 pathways to suppress tumor invasion .

• Clinical Utility: Linked to apoptosis regulation and biomarker potential in carcinomas .

• Technical Performance:

  • Western Blot: Linear detection at 1:20,000 dilution with minimal background .

  • Flow Cytometry: Specific signal in permeabilized HeLa cells (1:1000 dilution) .

Anti-PF4 Antibody (PA1446)

• Immunogen: Synthetic peptide corresponding to human PF4 C-terminus .

• Cross-Reactivity: Specific to human PF4; no cross-reactivity with other proteins .

• Molecular Weight: Observed at ~50 kDa in WB, aligning with PF4 tetrameric structure .

Comparative Analysis of Related Antibodies

Gaps and Ambiguities

• Terminology: "PPC4" may represent a typographical error or proprietary designation absent from public databases.

• Functional Overlaps: No antibodies directly named "PPC4" are documented in peer-reviewed literature. Research on PF4 or PDCD4 antibodies may provide indirect insights.